Tau Pathology

Tau Pathology

Tau Pathology

Overview

Tau Pathology plays an important role in the study of neurodegenerative . This page provides comprehensive information about this topic, including its , significance in disease processes, and therapeutic implications.

Introduction

tau-protein Pathology is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes 45 sites, approximately 3-4 fold more than normal tau. Key pathological sites:

| Site | Antibody/Epitope | Significance |
|------|-----------------|-------------|
| Ser202/Thr205 | AT8 | Most commonly used diagnostic marker; early phosphorylation event |
| Thr181 | AT270 | CSF p-tau181 biomarker |
| Thr217 | — | [p-tau217](/biomarkers/p-tau-217) — most accurate blood-based AD biomarker |
| Thr231 | AT180 | p-tau231 — earliest CSF change; reflects amyloid-beta-driven tau phosphorylation |
| Ser396/Ser404 | PHF-1 | late-stage phosphorylation; correlates with tangle maturity |
| Ser262 | 12E8 | Within KXGS motif in repeat domain; directly reduces MT binding |

Kinases and Phosphatases

Tau Pathology

Tau Pathology

Overview

Tau Pathology plays an important role in the study of neurodegenerative . This page provides comprehensive information about this topic, including its , significance in disease processes, and therapeutic implications.

Introduction

tau-protein Pathology is an important component in the neurobiology of neurodegenerative . This page provides detailed information about its structure, function, and role in disease processes 45 sites, approximately 3-4 fold more than normal tau. Key pathological sites:

| Site | Antibody/Epitope | Significance |
|------|-----------------|-------------|
| Ser202/Thr205 | AT8 | Most commonly used diagnostic marker; early phosphorylation event |
| Thr181 | AT270 | CSF p-tau181 biomarker |
| Thr217 | — | [p-tau217](/biomarkers/p-tau-217) — most accurate blood-based AD biomarker |
| Thr231 | AT180 | p-tau231 — earliest CSF change; reflects amyloid-beta-driven tau phosphorylation |
| Ser396/Ser404 | PHF-1 | late-stage phosphorylation; correlates with tangle maturity |
| Ser262 | 12E8 | Within KXGS motif in repeat domain; directly reduces MT binding |

Kinases and Phosphatases

Major tau kinases (hyperphosphorylation drivers):

• [gsk3](/entities/gsk3-beta)-beta (glycogen synthase kinase-3 beta): Phosphorylates the most AD-relevant sites; activated by amyloid-beta; inhibited by lithium and tideglusib
• [cdk5](/entities/cdk5)/p25: Constitutively activated when calpain cleaves p35 to p25; major contributor to AD tau hyperphosphorylation]
• DYRK1A: Priming kinase for gsk3-beta; overexpressed in Down syndrome (chromosome 21)
• MARK: Phosphorylates KXGS motifs; directly releases tau from microtubules
• CaMKII: Calcium-dependent kinase activated during excitotoxicity

• [pp2a](/entities/pp2a)/pp2a): Accounts for ~70% of tau phosphatase activity in the brain; activity is reduced ~50% in AD brain
• pp2a/pp2a) reduction is itself caused by upregulation of its inhibitors (I1PP2A, I2PP2A/SET) in AD

• Glycogen synthase kinase-3β ([GSK-3β): One of the most important tau kinases, phosphorylating tau at multiple Alzheimer's-relevant sites [^7]
• Cyclin-dependent kinase 5 (CDK5): Activated by p35/p39, phosphorylates tau at multiple sites
• Mitogen-activated protein kinases (MAPKs): Including ERK1/2 and p38 MAPK

• Protein phosphatase 2A (PP2A): The major phosphatase responsible for tau dephosphorylation, accounting for approximately 70% of tau phosphatase activity in the brain <small>Intrinsically disordered; binds MTs</small>"] --> PHOS"Hyperphosphorylated Tau<br/><small>Detaches from MTs; mislocalizes</small>"

style TAU fill:#e3f2fd,stroke:#1565c0
style PHOS fill:#fff3e0,stroke:#e65100
style OLIGO fill:#fce4ec,stroke:#c62828
style PHF fill:#f3e5f5,stroke:#6a1b9a
style NFT fill:#f3e5f5,stroke:#6a1b9a
style GHOST fill:#efebe9,stroke:#4e342e
style SPREAD fill:#fff3e0,stroke:#e65100
```

Tau oligomers are now considered the most neurotoxic species, preceding fibril formation and correlating with synaptic-dysfunction, mitochondrial damage, and membrane disruption.

Cryo-EM Structures of Tau Filaments

A transformative advance: cryo-EM has revealed that each tauopathy has a unique tau filament fold (Fitzpatrick et al., 2017):

| Disease | Filament Type | Tau Isoforms | Core Residues | Key Structural Feature |
|---------|--------------|-------------|---------------|----------------------|
| AD | PHF and SF | 3R+4R | R3-R4 (306-378) | C-shaped fold; β-helix |
| Pick's disease | Pick body filaments | 3R | R1, R3-R4 | Elongated J-shape |
| CBD | CBD filaments | 4R | R1-R4 (274-380) | Four-layered; distinctive β-arch |
| PSP | PSP filaments | 4R | R1-R4 (272-381) | Distinct from CBD despite 4R overlap |
| CTE | CTE filaments | 3R+4R | R3-R4 | Unique hydrophobic cavity |
| AGD | AGD filaments | 4R | Similar to PSP | Closely related to PSP fold |
| GGT | GGT filaments | 4R | R2-R4 | Distinct glial tauopathy |

These structures demonstrate that the same tau protein]//tau adopts disease-specific conformations, supporting the concept of prion-like conformational strains [@longitudinal].

Braak Staging

Tau pathology follows a stereotypical progression through defined brain regions (Braak & Braak, 1991):

| Braak Stage | Regions Affected | Clinical Correlation | Tau PET Pattern |
|-------------|-----------------|---------------------|-----------------|
| I-II (Transentorhinal) | Entorhinal [cortex, transentorhinal region | Clinically silent; pre-symptomatic | Medial temporal positivity |
| III-IV (Limbic) | hippocampus, amygdala, limbic cortex | Mild cognitive impairment (MCI) | Temporal and parietal spread |
| V-VI (Neocortical) | Association cortices → primary cortices | Moderate to severe dementia | Widespread cortical uptake |

The Braak staging pattern is now detectable in living patients using tau PET imaging (flortaucipir/18FMK-6240), enabling in vivo staging of AD 90% accuracy for AD diagnosis; approaching CSF performance

• Plasma p-tau181: Widely validated; distinguishes AD from non-AD dementias
• Plasma p-tau231: Earliest blood change, detectable at amyloid-beta+ stage before tau PET positivity

• Plasma p-tau181: Highly accurate for AD diagnosis
• Plasma p-tau217: Superior accuracy, correlates with amyloid status
• Plasma p-tau231: Detects early, preclinical changes### Tau PET Imaging
• Flortaucipir (18FAV-1451): FDA-approved first-generation tau PET tracer
• 18FMK-6240: Second-generation tracer with improved specificity; cryo-EM shows 1:1 binding in PHF cleft (Bhatt et al., 2024)
• 18FPI-2620: Detects both AD and non-AD (4R) tau
• 18FGTP1: Used in clinical trials as outcome measure

Biomarkers for Tau Pathology

• [p-tau181: Phosphorylated tau at threonine 181
• p-tau217: Phosphorylated tau at threonine 217
• p-tau231: Phosphorylated tau at threonine 231
• Neurofilament Light Chain: Axonal damage marker
• 14-3-3 Proteins: Neuronal damage markers

Therapeutic Approaches

Anti-Tau Immunotherapy

| Antibody | Target | Status (2025) | Key Results |
|----------|--------|---------------|-------------|
| Semorinemab | N-terminal tau (extracellular) | Phase 2 completed | No cognitive benefit in prodromal AD; modest effect in mild-moderate AD |
| Bepranemab | Mid-domain tau | Phase 2 | Slowed tau PET accumulation by ~60%; cognition data pending |
| E2814 | MTBR tau (seed-competent) | Phase 2/3 (DIAN
| JNJ-63733657 | p-tau217 | Phase 2 | Reduced CSF p-tau217 by >90% |
| Zagotenemab | Conformational tau | Phase 2 completed | Did not meet primary endpoints |

Tau Antisense Oligonucleotides (ASOs)

• BIIB080 (IONIS-MAPTRx): Intrathecal ASO targeting mapt mRNA; reduces total tau production
• Phase 1b: ~60% reduction in CSF total tau and p-tau
• Phase 2: Tau PET slowing observed
• FDA Fast Track designation (April 2025)
• Rationale: Reducing substrate availability prevents both loss-of-function (MT destabilization) and gain-of-function (aggregation) toxicity

Tau Aggregation Inhibitors

• LMTM (leuco-methylthioninium): Methylthioninium derivative; failed Phase 3 trials as add-on therapy; monotherapy analysis suggested possible benefit
• Second-generation aggregation inhibitors in preclinical development

Kinase Inhibitors

• gsk3-beta inhibitors: Tideglusib (Phase 2 in PSP — no benefit); lithium (epidemiological evidence for reduced dementia risk)
• DYRK1A inhibitors: Potential for Down syndrome-AD
• cdk5 inhibitors: Challenging due to broad cdk5 functions; p25-specific approaches in development

Phosphatase Activators

• pp2a/pp2a) activators: Sodium selenate (Phase 2 in PSP — increased pp2a/pp2a) activity; mixed cognitive results)
• Restoring pp2a/pp2a) activity to reduce tau hyperphosphorylation

External Links

• PubMed — Biomedical literature database
• Alzforum Therapeutics Database — Clinical trial tracker
• Allen Brain Atlas — Brain gene expression data

Background

The study of Tau Pathology has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying [ of neurodegeneration and continues to drive therapeutic development [@antibodies].

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions [^6].

See Also

• [Brain Regions Index](/brain-regions)
• [Proteins Index
• [immunotherapy
• [lecanemab](/entities/lecanemab)

Tauopathies Beyond Alzheimer's Disease

Tau pathology is not specific to alzheimers but occurs in several other neurodegenerative conditions:

Common Features

These share common pathogenetic including:

• Abnormal tau phosphorylation and aggregation
• Selective neuronal vulnerability
• Progressive clinical decline
• Variable involvement of other protein aggregates

CSF Biomarkers

Cerebrospinal fluid provide information about tau pathology:

• Total tau (t-tau: Elevated in AD, reflects neuronal damage
• Phosphorylated tau (p-tau: More specific for AD, correlates with tangle burden [@travaglini2026]
• p-tau181: Most widely used, correlates with tau PET
• p-tau217: Higher specificity, detects early changes
• p-tau235: Emerging biomarker

Research Priorities

Clinical Trial Landscape

Multiple anti-tau therapies are in various stages of clinical development, targeting:

• Tau aggregation
• Tau phosphorylation
• Tau clearance via immunotherapy
• Tau production (ASOs)

• --

Imported Legacy Notes

Tau Pathology in Neurodegenerative Disease

Tau pathology represents one of the most critical hallmarks of alzheimers and several other neurodegenerative conditions collectively known as tauopathies. The tau protein, encoded by the mapt (tau-protein gene on chromosome 17q21.31, plays essential roles in neuronal function under normal conditions but undergoes pathological transformations that contribute to neurodegeneration.

Brain Atlas Resources

The following resources provide additional data on tau protein and related genes:

• Allen Human Brain Atlas: MAPT (tau expression data — Search for mapt gene expression across brain regions
• Allen Mouse Brain Atlas: Mapt expression in mouse brain — Explore tau expression in mouse models
• Allen Cell Type Atlas: Cell type-specific RNA-seq data — View tau expression across different cell types
• BrainSpan Developmental Transcriptome: MAPT developmental expression — Tau expression across brain development

Recent Research (2025-2026)

Recent structural and assay developments in tau pathology] sharpen how conformational diversity, mutation-specific folding, and seeding competence are measured across alzheimers and related tauopathies.

• 2025: Seeding biosensor cell line that reproduces the Alzheimer tau fold (Journal of Biological Chemistry) provides a reproducible functional readout for Alzheimer-type tau] seeding activity.[@melen2025]
• 2025: Distinct tau filament folds in human MAPT mutants P301L and P301T (Nature Structural & Molecular Biology) demonstrates structurally distinct mutant-specific fibrils, supporting precision subgrouping within tauopathies.[@arenazaurquijo2025]
• 2025: Tau filaments with the Alzheimer fold in human mapt mutants V337M and R406W](https://pubmed.ncbi.nlm.nih.gov/40044789/) (Nature Structural & Molecular Biology) shows convergent Alzheimer-like fold adoption across additional pathogenic mapt backgrounds.[@arenazaurquijo2025a]

Visual Resources

Neurofibrillary Tangle Histopathology

!Annotated neurofibrillary tangles in Alzheimer's Disease

This histology image shows annotated neurofibrillary tangles relevant to Tau(//tau, alzheimers, and tauopathy progression staging.

Image attribution: Mikael Haggstrom, Histopathology of neurofibrillary tangles in Alzheimer's Disease - annotated (CC0)(https://commons.wikimedia.org/wiki/File:Histopathology_of_neurofibrillary_tangles_in_Alzheimer%27s_disease_-_annotated.jpg)

2026 Research Advances

Tau Biomarker-Based Diagnosis: Nelson and Jicha<a href="#references" class="ref-link" data-ref-text="Nelson & Jicha, Tau Biomarker-Based Diagnosis of Alzheimer's Disease. Neurology (2026)">X</a> analyze tau biomarker-based diagnosis of Alzheimer's Disease and the relationship between tau pathology and the anti-[amyloid-beta therapeutic window. This research advances precision medicine approaches for AD diagnosis and treatment selection.

<!-- ci040-visuals:tau-aggregation -->

Visual Summary

Pathway Flowchart

SVG Diagram

!tau-aggregation pathway diagram["/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg[/ci040-tau-aggregation-20260302t010810z.[svg"

Figure: tau aggregation pathway schematic generated for NeuroWiki.

Research Evidence

F-18 TKH5105 PET imaging study in AD patients and healthy controls to assess selective binding to pathological PHF tau deposition

F-18 TKH5105 selectively binds to pathological PHF tau deposition in living AD patients and differentiates diseased brains from healthy controls. AD patients showed high retention in temporal cortex (known high density of neurofibrillary tangles) compared to cerebellum. Healthy controls' uptake in inferior temporal cortex was identical to cerebellum activity. Also showed in vitro binding to glial tau pathology in corticobasal degeneration and PSP. Rapid entry into gray matter areas, no toxic events reported.

Model System: Human subjects - patients with Alzheimer's disease (n=not specified) and healthy controls

Statistical Significance: Not reported

James et al., (2015)

F-18 FDDNP imaging evaluation

FDDNP demonstrates binding to both beta-amyloid and tau pathology (was not designed as specific tau tracer)

Model System: Human subjects

Statistical Significance: Not reported

James et al., (2015)

Tau PET imaging in Alzheimer's disease patients

AD patients have significantly higher tau tracer retention than CN individuals. Binding in inferior lateral temporal, posterior cingulate, and lateral parietal regions matches known regional deposition of tau pathology. In atypical AD presentations, spatial pattern of retention matches underlying clinical phenotypes.

Model System: AD patients (prodromal and dementia stages)

Statistical Significance: p<0.05 for group differences between AD and CN

Leuzy et al., (2019)

Tau PET in primary tauopathies (CBS and PSP)

Regional pattern of tau pathology expected in these with relatively good discrimination from healthy volunteers. However, many ROIs coincide with areas showing off-target binding to MAO-B in basal ganglia, creating overlap across diagnostic groups. Longitudinal imaging shows increase in tracer binding with disease progression.

Model System: Patients with clinical diagnoses of corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)

Statistical Significance: Tracer binding correlates with clinical scores of functional impairment in PSP

Leuzy et al., (2019)

Histone modification analysis in AD brain

Normal aging leads to increases in H4K16ac; AD associated with H4K16ac loss in lateral temporal lobe including near AD susceptibility loci. Tau pathology correlates with H3K9ac dysregulation in up to 23% of all H3K9ac domains. Tau-related H3K9ac alterations cluster in large genomic segments covering several megabase pairs.

Model System: Human AD postmortem brain (lateral temporal lobe, [entorhinal cortex](/brain-regions/entorhinal-cortex), dorsolateral prefrontal cortex)

Statistical Significance: Not specified

Cláudio Gouveia Roque et al., (2024)

Neuropathological assessment of AD neuropathological change

All three subjects had intermediate to high AD neuropathological change. Braak stages: Case 1 (VI/V), Case 2 (IV/V), Case 3 (V/V). Thal phases: Cases 1 and 3 = 4 (high), Case 2 = 3 (intermediate). CERAD: Cases 1 and 3 frequent, Case 2 moderate. No atypical tau pathology identified in any case.

Model System: Human postmortem brain tissue

Statistical Significance: N/A - descriptive neuropathology

Pontecorvo et al., (2020)

Review of neuropathologic correlations between tau PET signal and postmortem tau pathology

Strong evidence that tau PET tracers (18F-flortaucipir, 18F-MK6240, 18F-RO948, 18F-PI2620) bind AD tau aggregates in advanced Braak stages (>IV). Accuracy for detecting tau load in Braak V-VI was 87.5% (95% CI, 77.2%-93.5%). Strong correlations (R2 range, 0.66-0.76) between tau PET levels and quantitative neuropathologic tau burden. Tracer binding weaker in non-AD tauopathies and overlaps with off-target regions.

Model System: Human postmortem brain tissue

Statistical Significance: R2 range 0.66-0.76 for AD tau correlations; 87.5% accuracy for Braak V-VI detection

Groot et al., (2022)

A16 Primary Cohort diagnostic study - Prospective evaluation of 18Fflortaucipir PET imaging compared to postmortem assessment of tau pathology and AD neuropathological change

Flortaucipir PET predicted B3-level tau pathology with sensitivity 92.3-100% and specificity 52.0-92.0%. Predicted high ADNC with sensitivity 94.7-100% and specificity 50.0-92.3%. Majority read analysis showed 92.3% sensitivity and 80.0% specificity for B3, 94.7% sensitivity and 80.8% specificity for high ADNC. Inter-rater reliability high (Fleiss k=0.74, P<.001). SUVR cutpoint >1.113 yielded 84.2% sensitivity for B3 and 86.5% for high ADNC with 100% specificity.

Model System: Human participants with terminal illness (n=64 in primary cohort; 156 enrolled total; 67 autopsied)

Statistical Significance: P<.001 for inter-rater reliability; 95% CI ranges provided for all sensitivity/specificity values

Fleisher et al., (2020)

18F-T807/AV-1451 longitudinal study and correlation studies

Tau pathology appears in [hippocampus](/brain-regions/hippocampus), parahippocampus, and entorhinal cortex in early dementia stages. Increased tau in inferior temporal lobe associated with worse memory. CSF tau levels correlated with tau imaging in 6 brain regions consistent with Braak staging. Test/retest reproducibility ~4-5%. ~10% year-over-year increase in mean cortical SUVR in high amyloid burden subjects. Increased tau accompanied by lower MMSE performance.

Model System: Human subjects from Harvard Aging Brain Study (75 older subjects)

Statistical Significance: Statistically significant correlations between CSF tau and tau PET in entorhinal/parahippocampal regions, inferior temporal, middle temporal, and superior temporal cortices

Hartmuth C. Kolb, José Ignacio Andrés (2017)

Subcellular resolution autoradiography of T807 binding

T807 perfectly colocalized with tau-containing neurons/neurons) and dystrophic neurites. Confirmed strong T807 binding to tau pathology in AD but not to cerebral amyloid, DLB, MSA, or [TDP-43](/mechanisms/tdp-43-proteinopathy). Tangles and dystrophic neurites account for most of the in vivo T807 signal.

Model System: Human AD brain tissue

Statistical Significance: N/A

Hartmuth C. Kolb, José Ignacio Andrés (2017)

Immunohistochemical analysis of 6 representative human amygdalae for Ab, Tau, alpha-synuclein, and TDP-43 pathology

Cases showed: (1) pathology often exists around the periphery of amygdalae near meninges and/or lateral ventricle; (2) peri-amygdaloid grey matter including entorhinal cortex frequently shows pathologies; (3) cortical and transitional regions are vulnerable; (4) phospho-Tau pathology is constant in all aged individuals. Cases 3-6 showed comorbid Ab, Tau, a-synuclein, and TDP-43 pathologies.

Model System: Human postmortem amygdala tissue (UK-ADC autopsy cohort)

Statistical Significance: Not applicable (descriptive case series)

Nelson et al., (2018)

Analysis of p-tau accumulation in LC across lifespan

p-tau begins to accumulate in LC early in life, in some cases as young as 10 years of age; 90% of individuals have some tau pathology in LC by age 30; 72% of individuals aged 31-40 years have tau lesions; 94% of individuals aged 41-50 years have tau lesions

Model System: Human postmortem brain tissue

Statistical Significance: Not reported

Matchett et al., (2021)

Additional evidence sources: [@shortlived] [@bloodbased] [@association] [^8] [^9] [^10] [^11] [^12] [@stern2026] [@kumar2026] [@pourshafie2026] [@mcdade2025]

Recent Research Updates (2024-2026)

This section highlights recent publications relevant to this mechanism.

• Short-lived Niemann-Pick type C mice with accelerated brain aging as a novel model for Alzheimer's disease research. (2026 Jun 1) - Neural regeneration research
• Blood-based for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration. (2026 May) - Ageing research reviews
• Longitudinal Metabolic Alterations of the Visual Cortex in Diabetic Retinopathy Rats Using High-Field Proton Magnetic Resonance Spectroscopy. (2026 Apr) - NMR in biomedicine
• Association between sleep duration and fluid of Alzheimer's disease: A systematic review. (2026 Apr) - Sleep medicine reviews
• Antibodies in Creutzfeldt-Jakob disease: A systematic review of patient characteristics, diagnostics, and clinical implications. (2026 Apr) - Journal of neuroimmunology

References

[@roemercassiano2025]: Roemer-Cassiano SN et al., Amyloid-associated hyperconnectivity drives tau spread across connected brain regions in Alzheimer's disease. Brain (2025).
[@welikovitch2025]: Welikovitch LA et al., Tau, synapse loss and gliosis progress in an Alzheimer's mouse model after amyloid-beta immunotherapy. Nat Commun (2025).
[@arnsten2025]: Arnsten AFT et al., An integrated view of the relationships between amyloid, tau, and inflammatory pathophysiology in Alzheimer's disease. Nat Rev Immunol (2025).
[@hou2025]: Hou K et al., How short peptides disassemble tau fibrils in Alzheimer's disease. Nat Commun (2025).

Related Mechanisms

• Cerebral Amyloid Angiopathy Pathway — CAA as a comorbidity in tau pathology

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 25 references |
| Replication | 33% |
| Effect Sizes | 75% |
| Contradicting Evidence | 33% |
| Mechanistic Completeness | 50% |

Overall Confidence: 65%